A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Clinical trial NCT05899816 · COMPLETED

Trial details

NCT number: NCT05899816
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis Moderate-to-severe Atopic Dermatitis

Start date: 2023-06-07
Primary completion: 2024-08-26
Enrollment: 221

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.